Is DPA a metabolic bridge between EPA and DHA and linked to cardiometabolic risk?

Docosapentaenoic acid (DPA) is an intermediary long-chain omega-3 fatty acid that occupies a central role in human fatty acid metabolism, positioned between eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Mechanistic explanations

DPA synthesis and conversion are governed by a specific set of enzymatic pathways:

• EPA to DPA Elongation: EPA is elongated into DPA by the addition of two carbons. This process is primarily mediated by the enzymes ELOVL2 and ELOVL5 on the endoplasmic reticulum membrane. ELOVL2, in particular, shows a strong preference for EPA, making it the dominant driver of DPA production.
• DPA to DHA Conversion: The progression from DPA to DHA occurs through the Sprecher pathway. This requires an additional elongation step (converting DPA to tetracosapentaenoic acid, 24:5n-3), a Delta-6 desaturation by the FADS2 enzyme, and a final peroxisomal beta-oxidation step to yield DHA.
• Pathway Regulation: While the mechanism is well-defined, the flux toward DHA is restricted in humans. Interestingly, dietary DHA can act as a feedback inhibitor, suppressing the ELOVL2-mediated conversion of EPA to DPA. Furthermore, DPA is frequently retroconverted back into EPA, creating a dynamic metabolic cycle.

Clinical and effectiveness evidence

Large-scale observational research consistently identifies circulating DPA as a robust biomarker for cardiometabolic health:

• Type 2 Diabetes (T2D) Risk: In a landmark pooled analysis of 20 prospective cohorts (n > 65,000), DPA demonstrated the strongest inverse association with incident T2D among all long-chain omega-3s. The study reported a hazard ratio (HR) of 0.79 per interquintile range, indicating that higher DPA levels are associated with a 21% reduction in diabetes risk.
• Cardiovascular Protection: Higher circulating DPA levels are significantly associated with a lower risk of total cardiovascular disease and fatal coronary heart disease. Evidence from the Cardiovascular Health Study suggests DPA is specifically linked to a reduced risk of cardioembolic stroke and total mortality, with associations often independent of EPA and DHA levels.
• Metabolic Syndrome: Low levels of DPA in plasma phospholipids and erythrocytes are frequently observed in individuals with metabolic syndrome compared to healthy controls, reinforcing its role as a marker for metabolic stability.

Bottom line

DPA is a critical metabolic bridge between EPA and DHA, and its circulating levels are a powerful indicator of cardiometabolic health. Evidence strongly suggests that lower DPA levels are associated with a significantly higher risk of type 2 diabetes and fatal cardiovascular events, highlighting its independent clinical importance beyond better-known omega-3s like EPA and DHA.